Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Total Liabilities (2016 - 2025)

Arrowhead Pharmaceuticals' Total Liabilities history spans 16 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Total Liabilities rose 8.16% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, up 8.16%, while the annual FY2025 figure was $881.9 million, 7.05% down from the prior year.
  • Total Liabilities reached $1.0 billion in Q4 2025 per ARWR's latest filing, up from $881.9 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $1.0 billion in Q4 2025 to a low of $251.3 million in Q1 2022.
  • Average Total Liabilities over 5 years is $541.1 million, with a median of $456.2 million recorded in 2023.
  • Peak YoY movement for Total Liabilities: skyrocketed 493.98% in 2021, then dropped 19.26% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $266.0 million in 2021, then surged by 86.15% to $495.1 million in 2022, then decreased by 8.59% to $452.6 million in 2023, then skyrocketed by 111.59% to $957.6 million in 2024, then grew by 8.16% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Total Liabilities are $1.0 billion (Q4 2025), $881.9 million (Q3 2025), and $858.3 million (Q2 2025).